CD4 and tuberculosis: A recent phase 2 double-blind, placebo-controlled trial (‘RADIANT-TB’) in patients with CD4 + T cells > 100 cells/microL found comparable virological suppression in participants randomised to a second 50 mg DTG dose or placebo (in combination with a daily single tablet regimen of DTG/TDF/3TC [69].